Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02813252 · ClinicalTrials.gov registry record
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
A clinical trial of Acute Lymphoblastic Leukemia, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- 15
- Enrollment target
- 4
- Study locations
NCT02813252: Completed study of Acute Lymphoblastic Leukemia, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
NCT02813252 is a study of Acute Lymphoblastic Leukemia that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 15 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02813252, a study of Acute Lymphoblastic Leukemia, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.
Conditions Studied
Interventions
- GENETIC JCAR015
Study Locations (4)
Illinois
- Northwestern University - Chicago
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Missouri
- Washington University School of Medicine - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2021-10-22 |
What the finished NCT02813252 record still lists
NCT02813252 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which JCAR015 is the first listed.
NCT02813252 reports a single indexed study location in Illinois, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT02813252 about?
NCT02813252 is a clinical study titled "Long-Term Follow-up Study for Patients Previously Treated With JCAR015". This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector...
What is the current status of trial NCT02813252?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2016-08-30. Estimated completion is 2021-10-22.
What conditions does trial NCT02813252 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT02813252?
The interventions under investigation include: JCAR015 (GENETIC).
Who is sponsoring clinical trial NCT02813252?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02813252 being conducted?
This trial has 4 study locations across Illinois, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02813252's enrollment target sits among peer trials
15 114th of 131 higher than 14 of 131 other Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI